PLEKHB2

Across TCGA pan-cancer cohorts, PLEKHB2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PLEKHB2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where PLEKHB2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PLEKHB2 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

PDAC, CCRCC, and LSCC are the cancer types where PLEKHB2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLEKHB2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	+0.931	<.001	7	view →
CCRCC	Male	III,IV	−0.284	<.001	6	view →
LSCC	Male	All	−0.169	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PLEKHB2–PDAC

Open the PDAC breakdown →